Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > "impressive, paradigm shifting, photodynamic therapy"

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Feb 23, 2023 5:20pm

175 Views

Post# 35302069

RE:RE:RE:RE:"impressive, paradigm shifting, photodynamic therapy"

I wonder when the last time Dr. Uddin looked at the AA criteria? Has that changed from 20-25 to 100-125? Since we all last looked? I think TLT has been very conservative that in their PRs they use 2024 a lot. It might be that long but likely due to FDA delays and delays at the clinic. The patients needed have already been treated, IMO.

If what your thinking is correct though, Imagine how good the CR data will look then? It already beats Keytruda now... :-)

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”